News
-
-
-
-
PRESS RELEASE
Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
Berenberg initiates coverage on Eckert & Ziegler SE with a "Buy" recommendation and €24 price target, highlighting market position and rising demand for radioisotopes in nuclear medicine -
-
PRESS RELEASE
Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
Eckert & Ziegler SE reports a further increase in earnings in the first half of 2025, with sales of €148.8 million and net income of €21.4 million. Confirmed forecast for 2025: sales around €320 million and EBIT around €78 million -
-
PRESS RELEASE
Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
Eckert & Ziegler SE implements share split, issuing bonus shares effective August 15, 2025, tripling tradable shares for improved liquidity without changing shareholder percentages -
-
PRESS RELEASE
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler chosen as US manufacturer for Archeus' ART-101 radiopharmaceutical, targeting prostate cancer. Collaboration to support Phase 1 trial with state-of-the-art facility in Boston, MA